| Medical and Health Sciences | Lifetime | 434 | AU 25 | 99.98 |
| Medical and Health Sciences | 2021-2025 | 350 | AU 15 | 99.93 |
| Surgery | Lifetime | 51 | AU 3 | 99.95 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 92 | AU 6 | 99.71 |
| Cardiology and Cardiovascular Medicine | Lifetime | 339 | AU 12 | 99.56 |
| Cancer Research | Lifetime | 271 | AU 8 | 98.41 |
| Nutrition and Dietetics | Lifetime | 913 | AU 44 | 95.47 |
| Nephrology | Lifetime | 583 | AU 32 | 93.18 |
| Surgery | 2021-2025 | 18 | AU 2 | 99.88 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 132 | AU 6 | 99.34 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 190 | AU 6 | 96.58 |
| Cancer Research | 2021-2025 | 196 | AU 2 | 89.67 |
| Cancer, Lipids, and Metabolism | Lifetime | 22 | AU 1 | 99.84 |
| Lipid metabolism and disorders | Lifetime | 11 | AU 1 | 99.69 |
| Lipoproteins and Cardiovascular Health | Lifetime | 22 | AU 1 | 99.83 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 30 | AU 4 | 99.83 |
| Cardiovascular Health and Disease Prevention | Lifetime | 96 | AU 5 | 99.37 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 245 | AU 10 | 99.25 |
| Cholesterol and Lipid Metabolism | Lifetime | 79 | AU 4 | 98.75 |
| Pharmaceutical Economics and Policy | Lifetime | 70 | AU 3 | 98.57 |
| Cardiovascular Disease and Adiposity | Lifetime | 225 | AU 5 | 98.73 |
| Liver Disease Diagnosis and Treatment | Lifetime | 942 | AU 25 | 98.86 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 190 | AU 4 | 98.47 |
| Fatty Acid Research and Health | Lifetime | 199 | AU 14 | 98.22 |
| Coenzyme Q10 studies and effects | Lifetime | 33 | AU 2 | 97.86 |
| Peroxisome Proliferator-Activated Receptors | Lifetime | 255 | AU 4 | 98.02 |
| Blood Pressure and Hypertension Studies | Lifetime | 513 | AU 32 | 98.51 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 432 | AU 4 | 98.13 |
| Health and Medical Research Impacts | Lifetime | 138 | AU 5 | 96.23 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 413 | AU 16 | 98.13 |
| Chronic Kidney Disease and Diabetes | Lifetime | 429 | AU 28 | 97.72 |
| Diet, Metabolism, and Disease | Lifetime | 635 | AU 25 | 97.10 |
| Aortic Thrombus and Embolism | Lifetime | 39 | AU 2 | 95.88 |
| Pharmacology and Obesity Treatment | Lifetime | 578 | AU 22 | 94.22 |
| Vitamin K Research Studies | Lifetime | 383 | AU 8 | 90.59 |
| Clinical Laboratory Practices and Quality Control | Lifetime | 858 | AU 31 | 80.11 |
| Lipid metabolism and disorders | 2021-2025 | 3 | AU 1 | 99.19 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 19 | AU 2 | 99.44 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 18 | AU 2 | 99.40 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 19 | AU 2 | 99.57 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 87 | AU 8 | 98.66 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 40 | AU 3 | 98.59 |
| Health and Medical Research Impacts | 2021-2025 | 17 | AU 1 | 95.39 |
| Cholesterol and Lipid Metabolism | 2021-2025 | 40 | AU 1 | 90.94 |
| Acute Myocardial Infarction Research | 2021-2025 | 620 | AU 21 | 93.00 |
| Inflammatory mediators and NSAID effects | 2021-2025 | 161 | AU 12 | 84.85 |
| Pharmaceutical Economics and Policy | 2021-2025 | 282 | AU 6 | 86.57 |
| Aortic Thrombus and Embolism | 2021-2025 | 33 | AU 1 | 77.55 |
| Caveolin-1 and cellular processes | 2021-2025 | 228 | AU 15 | 53.53 |
| Vitamin K Research Studies | 2021-2025 | 462 | AU 30 | 42.59 |
